Backbone Modification Provides a Long-Acting Inverse Agonist of Pathogenic, Constitutively Active PTH1R Variants

Shi Liu,Eileen J. Daley,Lauren My-Linh Tran,Zhen Yu,Monica Reyes,Thomas Dean,Ashok Khatri,Paul M. Levine,Aaron T. Balana,Matthew R. Pratt,Harald Jüppner,Samuel H. Gellman,Thomas J. Gardella,Harald Jüppner
DOI: https://doi.org/10.1021/jacs.3c09694
IF: 15
2024-02-29
Journal of the American Chemical Society
Abstract:Parathyroid hormone 1 receptor (PTH1R) plays a key role in mediating calcium homeostasis and bone development, and aberrant PTH1R activity underlies several human diseases. Peptidic PTH1R antagonists and inverse agonists have therapeutic potential in treating these diseases, but their poor pharmacokinetics and pharmacodynamics undermine their in vivo efficacy. Herein, we report the use of a backbone-modification strategy to design a peptidic PTH1R inhibitor that displays prolonged activity as an...
chemistry, multidisciplinary
What problem does this paper attempt to address?